Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Grootendorst

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Pharmacoepidemiology and Drug Safety|June 21, 2011
Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysisJohn Paul Leombruno, Geoffrey C Nguyen, Paul Grootendorst, et al.
Statistics in Medicine|June 20, 2006
Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo studyPeter C Austin, Paul Grootendorst, Sharon-Lise T Normand, et al.
The Journal of Rheumatology|March 9, 2007
A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the kneePaul Grootendorst, Deborah Marshall, Dan Pericak, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan dataFrank R Lichtenberg, Paul Grootendorst, Marc Van Audenrode, et al.
Orphanet Journal of Rare Diseases|January 12, 2019
Estimating the clinical cost of drug development for orphan versus non-orphan drugsKavisha Jayasundara, Aidan Hollis, Murray Krahn, et al.
Vaccine|July 9, 2013
Toward more specific and transparent research and development costs: the case of seasonal influenza vaccinesAyman Chit, Jayson Parker, Scott A Halperin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|May 27, 2024
The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort studyWei Zhang, Huiying Sun, Daphne P Guh, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 12, 2019
The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approachAysegul Erman, William W L Wong, Jordan J Feld, et al.
JAMA Network Open|June 30, 2020
Development and Validation of a Clinical Prediction Tool for Seasonal Influenza Vaccination in EnglandMatthew M Loiacono, Nicholas Mitsakakis, Jeffrey C Kwong, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 4, 2025
The relationship between osteoporosis treatment history and receipt of a second zoledronic acid doseNatalia Konstantelos, Sandra Kim, Angela M Cheung, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Pharmacoepidemiology and Drug Safety|June 21, 2011
Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysisJohn Paul Leombruno, Geoffrey C Nguyen, Paul Grootendorst, et al.
Statistics in Medicine|June 20, 2006
Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo studyPeter C Austin, Paul Grootendorst, Sharon-Lise T Normand, et al.
The Journal of Rheumatology|March 9, 2007
A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the kneePaul Grootendorst, Deborah Marshall, Dan Pericak, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan dataFrank R Lichtenberg, Paul Grootendorst, Marc Van Audenrode, et al.
Orphanet Journal of Rare Diseases|January 12, 2019
Estimating the clinical cost of drug development for orphan versus non-orphan drugsKavisha Jayasundara, Aidan Hollis, Murray Krahn, et al.
Vaccine|July 9, 2013
Toward more specific and transparent research and development costs: the case of seasonal influenza vaccinesAyman Chit, Jayson Parker, Scott A Halperin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|May 27, 2024
The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort studyWei Zhang, Huiying Sun, Daphne P Guh, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 12, 2019
The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approachAysegul Erman, William W L Wong, Jordan J Feld, et al.
JAMA Network Open|June 30, 2020
Development and Validation of a Clinical Prediction Tool for Seasonal Influenza Vaccination in EnglandMatthew M Loiacono, Nicholas Mitsakakis, Jeffrey C Kwong, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 4, 2025
The relationship between osteoporosis treatment history and receipt of a second zoledronic acid doseNatalia Konstantelos, Sandra Kim, Angela M Cheung, et al.
Pageof 8